Latest Car T News

FleetPartners Group Limited reported a 7.3% rise in half-year profit to $37.05 million, driven by lease portfolio growth and the integration of Remunerator. The company declared an 11.9 cent fully franked interim dividend and confirmed a positive outlook for FY26.

Smartgroup delivered a robust start to 2026 with double-digit growth in novated leasing orders and a new app rollout, while targeting mid-40s EBITDA margins for 2027 amid supportive EV policies.

Arovella Therapeutics undergoes a major board overhaul and CEO resignation following a shareholder push, as the company embarks on a strategic review of its cell therapy platform.

AdAlta has secured A$2.5 million in a strategic placement to push its lead CAR-T therapy BZDS1901 through critical US FDA regulatory steps and establish Australian manufacturing, building on promising clinical responses in advanced mesothelioma.

Jayride Group continues its pivot to a SaaS mobility platform across Australasia and Southeast Asia, managing tight cash flow and planning a capital raise to sustain operations and support ASX reinstatement.

NH3 Clean Energy’s WAH2 project is projected to deliver substantial economic and environmental benefits, including a $7.3 billion GDP uplift and 13.5 million tonnes of CO2 emissions avoided, underpinning its push for government-backed concessional financing.

Mesoblast Limited posted US$30.3 million in net revenues for Ryoncil® in Q3 2026, hitting key clinical milestones and securing new technology licenses that could boost its next-generation cell therapies.

AdAlta has launched its East-to-West cellular immunotherapy strategy through a co-development deal for CAR-T therapy BZDS1901, showing promising complete tumour clearance in mesothelioma patients and transferring manufacturing to Australia to boost scalability.

AdAlta has secured Australian manufacturing for its lead CAR-T therapy BZDS1901, which has shown rare complete tumour clearance in advanced mesothelioma patients. This move is a key step toward local clinical trials and boosts the therapy’s global commercial appeal.

INOVIQ Limited is on track to complete its EXO-OC™ ovarian cancer screening study by mid-2026 and is accelerating its CAR-exosome therapy program, supported by a strong cash position of A$11.9 million.

Barramundi Limited’s portfolio took a heavy hit in Q1 2026, with a 15.4% adjusted NAV decline amid AI disruption anxieties and geopolitical tensions. The fund responded by trimming tech holdings and adding miners BHP and Rio Tinto, betting on copper demand and scale advantages.

Chimeric Therapeutics' CHM CORE-NK cell therapy achieved a 60% complete response rate in high-risk frontline AML patients, significantly exceeding typical outcomes and maintaining a strong safety profile.